When Ozempic and Wegovy launched, their bombshell success was only going to be exclusive to their maker—Novo Nordisk—for a matter of time. While the Danish pharma giant holds the patents to these GLP-1s for the time being, some are due to expire as early as next year.

The success of these drugs, used to treat diabetes and obesity, has naturally caught the attention of Novo’s competitors. America’s Eli Lilly , for example, is seeing growing demand for its Mounjaro product and is keen for a pill form of the medication to be pushed speedily through the U.S. approvals process.

Novo Nordisk has a pill form of its own products to come, but the fact remains that until it can conjure its next rabbit from the hat, the outlook is weakening. In its Q3 2025 results released November 5, Novo repo

See Full Page